Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals

Trial Profile

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 08 May 2017

At a glance

  • Drugs Enfuvirtide (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2016 Planned End Date changed from 1 Jul 2017 to 1 Jul 2021, as reported by ClinicalTrials.gov record.
    • 08 Mar 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2020, as reported by ClinicalTrials.gov record.
    • 10 Jun 2015 Planned number of patients changed from 10 to 20, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top